airway cells - viral infection
Respiratory Assays
Airway Cells - Viral Infection
Our airway viral infection models enable researchers to investigate host–pathogen interactions and evaluate cellular responses to respiratory viral infections under controlled laboratory conditions. These physiologically relevant in vitro systems are designed to mimic key features of the human airway environment, allowing detailed analysis of viral entry, replication, and spread within airway epithelial cells. By providing clinically relevant data, our airway viral infection models help advance the development of antiviral therapies, respiratory disease treatments, and preventative strategies against emerging viral threats.
Cytokine release after Respiratory Syncytial Virus (RSV) infection
Time-course of A549 cell viability and cytotoxicity (LDH release) following hRSV infection.
A549 cells were infected with hRSV (3 MOIs). Viability was measured by CellTiterGlo® assay at days 1, 2, 3, and 9 vs uninfected control, in technical triplicates. % LDH release was measured by LDH-GLO® assay at days 3, 5, and 7 post infection relative to Triton X-100 positive control, in technical triplicates.
Cytokine release after RSV infection and Dexamethasone treatment
Dexamethasone modulates hRSV-induced inflammatory mediator release in A549 cells.
A549 cells infected with hRSV ± dexamethasone; panel of cytokines quantified in culture supernatants by Luminex Assay (n=3). (Stats: one-way ANOVA; n as stated; mean ± SEM; *p<0.05, **p<0.01, ***p<0.001)
Cytokine release after RSV infection and Presatovir treatment
Presatovir modulates hRSV-induced inflammatory responses in A549 cells.
A549 cells were infected with hRSV in the presence or absence of Presatovir; a panel of cytokines/chemokines was quantified in culture supernatants using the Luminex Assay at 24 and 72 hours post-infection (n = 3). (Stats: one-way ANOVA; n as stated; mean ± SEM; *p<0.05, **p<0.01, ***p<0.001)
Cytokine release after RSV infection and Ribavirin treatment
Ribavirin modulates hRSV-induced inflammatory mediator release in A549 cells.
A549 cells were infected with hRSV ± Ribavirin; a panel of cytokines and chemokines was quantified in culture supernatants using the Luminex Assay at 24 and 72 hours post-infection (n = 3). (Stats: one-way ANOVA; n as stated; mean ± SEM; *p<0.05, **p<0.01, ***p<0.001).
These airway viral infection models provide valuable insights into viral replication, immune activation, inflammatory signalling pathways, and the efficacy of potential antiviral therapies.
Request a consultation with Cellomatics Biosciences today
Cellomatics offers customised airway viral infection models to support respiratory disease research, translational studies, and the development of novel therapeutic interventions. Our experienced team of in vitro laboratory scientists will work with you to understand your project and provide a bespoke project plan with a professional, flexible service and a fast turnaround time.
To request a consultation where we can discuss your exact requirements, please contact Cellomatics Biosciences.
